FierceBiotech 2025-12-19 Merck turns down option to Evaxion's gonorrhea vaccine, prompting Danish biotech to seek other partners
FierceBiotech 2025-12-19 Galapagos ends turbulent year with mixed results for last remaining immunology asset
FierceBiotech 2025-12-18 Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A
FierceBiotech 2025-12-18 Verge Genomics drops sole clinical candidate in return to AI drug discovery roots
FierceBiotech 2025-12-18 Takeda looks to 2026 FDA filing for its Sotyktu rival zasocitinib after phase 3 success
FierceBiotech 2025-12-18 After HHS funding was scrapped, CEPI fronts up to $54M to carry Moderna's pandemic influenza vaccine into phase 3
FierceBiotech 2025-12-18 Lindus Health and Quotient team up to create one-stop shop for early to mid-stage trials
FierceBiotech 2025-12-17 Oncology biotech Mythic and former fundraising heavyweight Areteia reach end of road